Old Web
English
Sign In
Acemap
>
Paper
>
P2.02-034 PD-L1 Expression Can Be a Prognostic Marker in EGFR Mutant NSCLC Patients Treated with Erlotinib
P2.02-034 PD-L1 Expression Can Be a Prognostic Marker in EGFR Mutant NSCLC Patients Treated with Erlotinib
2017
Niki Karachaliou
Andrés F. Cardona
M. González Cao
A. Giménez-Capitán
Ana Drozdowskyj
Erika Aldeguer
Guillermo Lopez-Vivanco
J. M. Sánchez Torres
M. De Los Llanos Gil
M. Molina-Vila
R. Rosell
Keywords:
General surgery
PD-L1
Cancer research
Erlotinib
Mutant
Medicine
pd l1 expression
Pathology
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]